Longevity Technology: ‘Exclusive profile: LyGenesis and growing ectopic organs’

Michael Hufford , CEO of LyGenesis Inc. , speaks with Longevity Technology about revolutionary regenerative technology and plans for clinical development.

LyGenesis’ technology will enable the use of patients’ lymph nodes as bioreactors to regrow functioning ectopic organs to support or replace failing organs. Their initial target indication is end-stage liver disease (ESLD), utilizing a hepatocyte cell therapy product implanted into the periduodenal lymph nodes, which engraft, vascularize and perform all functions typical to liver tissue, enabling them to rescue patients from ESLD.

This allows a single donated liver to act as the seed for dozens of transplants using outpatient endoscopy. Likely to be classified as a cell therapy, it represents a near-term example of regenerative medicine.

There are currently no approved treatments for ESLD. LyGenesis’ technology could revolutionize the transplant market, allowing patients to avoid the requirement for liver transplant along with extending the lifespan of those unsuited to a liver transplant.

Read the full article at Longevity Technology.